Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02954874 · ClinicalTrials.gov registry record · Phase 3
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
A Phase 3 study of Invasive Breast Carcinoma and Triple-Negative Breast Carcinoma, sponsored by National Cancer Institute (NCI).
- Active
- Registry status
- Phase 3
- Development phase
- 1,155
- Enrollment target
- 20
- Study locations
NCT02954874 is a Phase 3 study of Invasive Breast Carcinoma and Triple-Negative Breast Carcinoma that is active but no longer recruiting, run by National Cancer Institute (NCI). The registered enrollment target is 1,155 participants, above the 459-participant average among 45 other Invasive Breast Carcinoma trials with a reported enrollment target (152% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT02954874, a Phase 3 study of Invasive Breast Carcinoma and Triple-Negative Breast Carcinoma, is active but no longer recruiting, sponsored by National Cancer Institute (NCI).
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,155 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized phase III trial studies how well pembrolizumab works in treating patients with triple-negative breast cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Conditions Studied
Interventions
- BIOLOGICAL Pembrolizumab
- PROCEDURE Biospecimen Collection
- OTHER Quality-of-Life Assessment
- OTHER Laboratory Biomarker Analysis
- OTHER Patient Observation
Study Locations (20)
Alabama
- University of Alabama at Birmingham Cancer Center - Birmingham
- Southern Cancer Center PC-Daphne - Daphne
- Southern Cancer Center PC-Mobile - Mobile
- Southern Cancer Center PC-Providence - Mobile
- Southern Cancer Center PC-Springhill - Mobile
- University of South Alabama Mitchell Cancer Institute - Mobile
Alaska
- Alaska Oncology and Hematology LLC - Anchorage
- Anchorage Oncology Centre - Anchorage
- Katmai Oncology Group - Anchorage
- Providence Alaska Medical Center - Anchorage
- Fairbanks Memorial Hospital - Fairbanks
Arizona
- Banner MD Anderson Cancer Center - Gilbert
- CTCA at Western Regional Medical Center - Goodyear
- Banner University Medical Center - Tucson - Tucson
- University of Arizona Cancer Center-North Campus - Tucson
Arkansas
- NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro - Jonesboro
- University of Arkansas for Medical Sciences - Little Rock
- Highlands Oncology Group - Rogers - Rogers
California
- Kaiser Permanente-Anaheim - Anaheim
- Kaiser Permanente-Deer Valley Medical Center - Antioch
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,155 participants |
| Start Date | 2017-01-18 |
| Est. Completion | 2026-05-31 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02954874
The ClinicalTrials.gov registry entry for NCT02954874 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,155 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 459-participant average among 45 other Invasive Breast Carcinoma trials with a reported enrollment target (152% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Invasive Breast Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.
NCT02954874 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Alabama, Alaska, Arizona.
Frequently Asked Questions
What is clinical trial NCT02954874 about?
NCT02954874 is a clinical study titled "Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer". This randomized phase III trial studies how well pembrolizumab works in treating patients with triple-negative breast cancer. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to gro...
What is the current status of trial NCT02954874?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,155 participants. The study started on 2017-01-18. Estimated completion is 2026-05-31.
What conditions does trial NCT02954874 study?
This clinical trial studies the following conditions: Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma, Stage II Breast Cancer AJCC v6 and v7, Stage III Breast Cancer AJCC v7, Stage I Breast Cancer AJCC v7.
What interventions are being tested in trial NCT02954874?
The interventions under investigation include: Pembrolizumab (BIOLOGICAL), Biospecimen Collection (PROCEDURE), Quality-of-Life Assessment (OTHER), Laboratory Biomarker Analysis (OTHER), Patient Observation (OTHER).
Who is sponsoring clinical trial NCT02954874?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02954874 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Invasive Breast Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Metformin for the Treatment of Insulin Resistance in Women With Stage I-III Breast Cancer Completing Chemotherapy
RECRUITING · Phase 3
-
Platinum in Treating Patients With Residual Triple-Negative Breast Cancer Following Neoadjuvant Chemotherapy
ACTIVE NOT RECRUITING · Phase 3
-
Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy
ACTIVE NOT RECRUITING · Phase 3
-
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer
ACTIVE NOT RECRUITING · Phase 3
-
Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer
ACTIVE NOT RECRUITING · Phase 3
-
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
ACTIVE NOT RECRUITING · Phase 3
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.